TB‑500 represents the N‑terminal active fragment of thymosin beta‑4, specifically the heptapeptide sequence Ac‑LKKTETQ[1][2]. This region is responsible for the actin‑binding and cell‑migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB‑500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation[5][6]. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments[11]. Recent metabolic studies suggest TB‑500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity[12].
